Home › Polycystic Ovary Syndrome › NCT06143527

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for PCOS

Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cells for the Treatment of Polycystic Ovary Syndrome

Who can join

Ages 18 and older · Women

Inclusion Criteria:

• Ultrasound documented poly cystic ovary syndrome

Exclusion Criteria:

* Active infection
* Active cancer
* Chronic multisystem organ failure
* Pregnancy
* Clinically significant abnormalities on pre-treatment laboratory evaluation
* Medical condition that would (based on the opinion of the investigator) compromise patient's safety
* Continued drug abuse
* Previous organ transplant
* Hypersensitivity to sulfur
* Inability to supply proper informed consent

About the study

This trial will study the safety and efficacy of cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells delivered intravenously for the treatment of Polycystic Ovary Syndrome.

What is being tested

• Cultured allogeneic adult umbilical cord or placental derived mesenchymal stem cells (biological)

Sponsor: The Foundation for Orthopaedics and Regenerative Medicine · Participants: 20 · Started: Nov 16, 2023

Contact the study team

• Chadwick Prodromos, MD · Phone: 847-699-6810

Official record on ClinicalTrials.gov — NCT06143527

Locations in the U.S.

Conditions

• Polycystic Ovary Syndrome

From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.